NCT07607561Not yet recruitingPhase 2
A Randomization, Double-blind, Placebo-controlled, Parallel, Multicenter, Phase 2a Study to Evaluate the Efficacy and Safety of SCAI-005 Ophthalmic Solution in Subjects With Neovascular Age-related Macular Degeneration
SCAI Therapeutics0 sites50 target enrollmentStarted: November 1, 2026Last updated:
Trial Snapshot
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 50
Study Overview
Brief Summary
Trial to Evaluate the Safety and Efficacy of SCAI-005 Ophthalmic solution in Patients with Neovascular Age-related Macular Degeneration.
The purpose of this study is to investigate the efficacy, safety and tolerability of SCAI-005 Ophthalmic solution by dose in patients with neovascular Age-related Macular Degeneration (nAMD).
Detailed Description
Subjects who have been informed about the study and have voluntarily agreed to sign to participate in the study will be screened.
Subjects who meet the inclusion/exclusion criteria will be randomized in 2:2:1 ratio into SCAI-005 0.04% and SCAI-005 0.08% and Placebo group.
Efficacy will be assessed at Weeks 4, 8, and 12. Safety and tolerability will be assessed until 12 weeks after randomization.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 50 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Adults aged 50 years or older
- •Subjects who were diagnosed with nAMD in the study eye within 3 years prior to the Screening Visit, who demonstrated a treatment response to at least 3 repeated intravitreal injections of anti-VEGF IVT for nAMD, and whose last anti-VEGF IVT administration was more than 12 weeks prior to the planned date of the first administration of the investigational product.
- •Active MNV secondary to nAMD with a subfoveal component related to the MNV activity in the study eye as assessed by FA (evidence of leakage) or SD-OCT (presence of fluid) at screening
- •CST ≤ 450 μm at screening
- •BCVA ETDRS letter score of 80 letters to 25 letters in the study eye as measured by the ETDRS visual acuity chart at screening
Exclusion Criteria
- •Subjects with choroidal neovascularization in the study eye due to causes other than nAMD (however, polypoidal choroidal vasculopathy (PCV) can be enrolled)
- •Presence of scarring, fibrosis, or atrophy involving the fovea in the study eye at Screening
- •Subjects who have a hemorrhage in the subfoveal region of the study eye and in whom the subretinal hemorrhage area is ≥ 1 optic disk area
- •History of glaucoma surgery, vitrectomy, submacular surgery, or macular laser treatment (e.g., photodynamic therapy [PDT], laser photocoagulation, etc.) in the study eye
- •Subjects with vitreous hemorrhage in the study eye
- •History of ocular treatment (except for anti-VEGF IVT therapy), systemic treatment, or surgical intervention for the treatment of neovascular age-related macular degeneration (nAMD) in the study eye
- •Administration of intraocular, periocular, or intravitreal (IVT) steroid injection in the study eye within 24 weeks prior to Screening
- •Presence of diabetic retinopathy, diabetic macular edema, or other vascular diseases affecting the retina, other than neovascular age-related macular degeneration (nAMD), in either eye
- •History of endophthalmitis or idiopathic or autoimmune-related uveitis in either eye
- •Subjects with active macular neovascularization identified in the fellow eye at Screening
Investigators
Similar Trials
Recruiting
Phase 2
A Clinical Study Evaluating Licaminlimab for Dry Eye DiseaseDry Eye Disease (DED)NCT07548632Oculis160
Recruiting
Phase 2
Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior UveitisNCT07285070Novaliq GmbH20
Not yet recruiting
Phase 3
Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in AdultsOcular HyperemiaNCT07531043Alcon Research230
Not yet recruiting
Phase 4
Better corneal endothelium cell protection during cataract surgery in Type 2 Diabetes Mellitus patients using different Ophthalmic viscosurgical devicesCTRI/2025/09/094198Sankara eye hospital Guntur80
Not yet recruiting
Phase 2/3
EFFICACY OF VACHA,HARIDRA,SUNTHI BIDALAKA IN KLINNA VARTMA WITH REFERENCE TO SQUAMOUS CELL BLEPHARITIS.CTRI/2026/04/107715Vd Sneha Deshmukh64